All News

Click the title above to open the Pharmaceutical Executive December 2016 issue in an interactive PDF format.

“Volume is not a dirty word” was outgoing GSK head Sir Andrew Witty’s key message at last week’s FT Global Pharmaceutical Conference in London.

This year’s 19th annual European Health Forum Gastein (Austria) once again attempted to establish unity in the face of EU woes. But are the Gastein region’s “healing powers” on the wane?

Click the title above to open the Pharmaceutical Executive November 2016 issue in an interactive PDF format.

Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.

PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development.

Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.

Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.

A look at the EU plans for a European patent, and where the UK fits in the mix.

The chances are slim, but a new resolution in Europe on the subject could drum up support for a Brexit-like scenario.

Click the title above to open the Pharmaceutical Executive August 2016 issue in an interactive PDF format.

July 22, 2016

Click the title above to open the Pharmaceutical Executive July 2016 issue in an interactive PDF format.

In the healthcare industry, “patient centricity” is like comfort food – everyone knows what it is, but it can mean very different things to different people.

In this paper, we’ll explore opportunities pharma marketers have to create engaging experiences that will deliver new types of value to meet their targets’ evolving expectations.

Policy makers "simply are not taking seriously the corrosive effect of corruption", study says.

Top officials at EMA push the boat out on drug-pricing views.

Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.

Policymakers seek to limit prescribing while also encouraging innovative R&D.

Click the title above to open the Pharmaceutical Executive May 2016 issue in an interactive PDF format.